Depomed Inc. said a ruling Tuesday preserves its monopoly on the pain drug Gralise for a decade, allowing the small pharmaceutical company and its investors to breathe a huge sigh of relief.
According to a Depomed press release, U.S. District Judge Joel Pisano in Newark, N.J., upheld the validity of all seven of Depomed’s patents relating to Gralise, the company’s best-selling drug. The ruling, which followed a bench trial earlier this year, was still under seal at press time.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
